• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于大样本队列的胶质母细胞瘤免疫亚型与免疫图谱的鉴定。

Identification of glioblastoma immune subtypes and immune landscape based on a large cohort.

机构信息

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.

Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.

出版信息

Hereditas. 2021 Aug 19;158(1):30. doi: 10.1186/s41065-021-00193-x.

DOI:10.1186/s41065-021-00193-x
PMID:34412691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8377979/
Abstract

Glioblastomas (GBM) are the most common primary brain malignancy and also the most aggressive one. In addition, GBM have to date poor treatment options. Therefore, understanding the GBM microenvironment may help to design immunotherapy treatments and rational combination strategies. In this study, the gene expression profiles and clinical follow-up data were downloaded from TCGA-GBM, and the molecular subtypes were identified using ConsensusClusterPlus. Univariate and multivariate Cox regression were used to evaluate the prognostic value of immune subtypes. The Graph Structure Learning method was used for dimension reduction to reveal the internal structure of the immune system. A Weighted Correlation Network Analysis (WGCNA) was used to identify immune-related gene modules. Four immune subtypes (IS1, IS2, IS3, IS4) with significant prognosis differences were obtained. Interestingly, IS4 had the highest mutation rate. We also found significant differences in the distribution of the four subtypes at immune checkpoints, molecular markers, and immune characteristics. WGCNA identified 11 co-expressed module genes, and there were significant differences among the four subtypes. Finally, CD1A, CD1E, and IL23R genes with significant prognostic significance were selected as the final feature genes in the brown module. Overall, this study provided a conceptual framework for understanding the tumor immune microenvironment of GBM.

摘要

胶质母细胞瘤(GBM)是最常见的原发性脑恶性肿瘤,也是侵袭性最强的肿瘤。此外,到目前为止,GBM 的治疗选择有限。因此,了解 GBM 微环境有助于设计免疫疗法治疗和合理的联合策略。在这项研究中,从 TCGA-GBM 下载了基因表达谱和临床随访数据,并使用 ConsensusClusterPlus 确定了分子亚型。单变量和多变量 Cox 回归用于评估免疫亚型的预后价值。Graph Structure Learning 方法用于降维以揭示免疫系统的内部结构。使用加权相关网络分析(WGCNA)识别免疫相关基因模块。获得了具有显著预后差异的四个免疫亚型(IS1、IS2、IS3、IS4)。有趣的是,IS4 的突变率最高。我们还发现四个亚型在免疫检查点、分子标志物和免疫特征方面的分布存在显著差异。WGCNA 鉴定了 11 个共表达模块基因,四个亚型之间存在显著差异。最后,选择具有显著预后意义的 CD1A、CD1E 和 IL23R 基因作为棕色模块的最终特征基因。总的来说,这项研究为理解 GBM 的肿瘤免疫微环境提供了一个概念框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/2ffd993430ff/41065_2021_193_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/01cc1e977497/41065_2021_193_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/0b743b044394/41065_2021_193_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/0f516eb25fa2/41065_2021_193_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/c93fed355ee4/41065_2021_193_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/74ee9928a6cd/41065_2021_193_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/2ffd993430ff/41065_2021_193_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/01cc1e977497/41065_2021_193_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/0b743b044394/41065_2021_193_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/0f516eb25fa2/41065_2021_193_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/c93fed355ee4/41065_2021_193_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/74ee9928a6cd/41065_2021_193_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c87f/8377979/2ffd993430ff/41065_2021_193_Fig7_HTML.jpg

相似文献

1
Identification of glioblastoma immune subtypes and immune landscape based on a large cohort.基于大样本队列的胶质母细胞瘤免疫亚型与免疫图谱的鉴定。
Hereditas. 2021 Aug 19;158(1):30. doi: 10.1186/s41065-021-00193-x.
2
Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.鉴定脑胶质瘤的肿瘤抗原和免疫亚型,用于 mRNA 疫苗的开发。
Front Immunol. 2022 Feb 2;13:773264. doi: 10.3389/fimmu.2022.773264. eCollection 2022.
3
Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.胶质母细胞瘤的肿瘤抗原与免疫亚型:mRNA疫苗及个体化免疫治疗发展的基础
J Big Data. 2022;9(1):92. doi: 10.1186/s40537-022-00643-x. Epub 2022 Jul 14.
4
Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis.基于加权基因共表达网络分析鉴定与胶质母细胞瘤发生发展相关的免疫相关基因。
Front Immunol. 2020 Jul 16;11:1281. doi: 10.3389/fimmu.2020.01281. eCollection 2020.
5
Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort.基于结肠癌队列的免疫分子亚型及免疫图谱的鉴定与验证
Front Med (Lausanne). 2022 May 6;9:827695. doi: 10.3389/fmed.2022.827695. eCollection 2022.
6
Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.鉴定葡萄膜黑色素瘤的分子亚型系统和与免疫相关基因的四基因预后特征。
Exp Biol Med (Maywood). 2022 Feb;247(3):246-262. doi: 10.1177/15353702211053801. Epub 2021 Nov 7.
7
Construction of co-expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma.通过 WGCNA 构建与生存相关的共表达模块,并鉴定胶质母细胞瘤中的潜在预后生物标志物。
J Cell Mol Med. 2021 Feb;25(3):1633-1644. doi: 10.1111/jcmm.16264. Epub 2021 Jan 15.
8
New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.从单细胞 lncRNA 表达分析中获得胶质母细胞瘤精准治疗的新见解。
J Cancer Res Clin Oncol. 2021 Jul;147(7):1881-1895. doi: 10.1007/s00432-021-03584-9. Epub 2021 Mar 11.
9
Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer.三阴性乳腺癌的免疫分类与免疫图谱分析
Front Genet. 2021 Nov 2;12:710534. doi: 10.3389/fgene.2021.710534. eCollection 2021.
10
Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.系统识别、开发和验证涉及胶质母细胞瘤肿瘤免疫微环境的预后生物标志物。
J Cell Physiol. 2021 Jan;236(1):507-522. doi: 10.1002/jcp.29878. Epub 2020 Jun 22.

引用本文的文献

1
Elevated Antigen-Presenting-Cell Signature Genes Predict Stemness and Metabolic Reprogramming States in Glioblastoma.抗原呈递细胞特征基因升高预示胶质母细胞瘤的干性和代谢重编程状态
Int J Mol Sci. 2025 Aug 1;26(15):7411. doi: 10.3390/ijms26157411.
2
Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).抗 PD-1/PDL1 免疫疗法治疗胶质母细胞瘤的研究进展(综述)。
Mol Med Rep. 2024 Dec;30(6). doi: 10.3892/mmr.2024.13344. Epub 2024 Oct 4.
3
Immunological Roles of CCL18 in Pan‑Cancer and Its Potential Value in Endometrial Cancer.

本文引用的文献

1
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.高肿瘤突变负荷和T细胞激活与林奇综合征复发性胶质母细胞瘤患者对抗PD1治疗的长期反应相关。
Cancer Immunol Immunother. 2021 Mar;70(3):831-842. doi: 10.1007/s00262-020-02769-4. Epub 2020 Nov 3.
2
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.美国 2013-2017 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200.
3
CCL18在泛癌中的免疫作用及其在子宫内膜癌中的潜在价值
Mol Biotechnol. 2025 Jun;67(6):2399-2410. doi: 10.1007/s12033-024-01205-7. Epub 2024 May 30.
4
Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies.胶质母细胞瘤免疫治疗的放射基因组学生物标志物:磁共振成像研究的系统评价
Neurooncol Adv. 2024 Apr 5;6(1):vdae055. doi: 10.1093/noajnl/vdae055. eCollection 2024 Jan-Dec.
5
Immune Subtypes and Immune Landscape Analysis of Endometrial Carcinoma.子宫内膜癌的免疫亚型与免疫全景分析。
J Immunol. 2022 Oct 15;209(8):1606-1614. doi: 10.4049/jimmunol.2200329. Epub 2022 Sep 12.
6
A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.一个 13 基因标志物,用于预测肺鳞癌的预后和免疫治疗反应。
Sci Rep. 2022 Aug 11;12(1):13646. doi: 10.1038/s41598-022-17735-6.
7
Emerging Biomarkers for Immunotherapy in Glioblastoma.胶质母细胞瘤免疫治疗的新兴生物标志物
Cancers (Basel). 2022 Apr 12;14(8):1940. doi: 10.3390/cancers14081940.
8
Epithelial-Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer.基于上皮-间质转化的基因特征及不同分子亚型用于预测乳腺癌临床结局
Int J Gen Med. 2022 Mar 30;15:3497-3515. doi: 10.2147/IJGM.S343885. eCollection 2022.
IL-23R in laryngeal cancer: a cancer immunoediting process that facilitates tumor cell proliferation and results in cisplatin resistance.
白细胞介素-23受体在喉癌中的作用:一种促进肿瘤细胞增殖并导致顺铂耐药的癌症免疫编辑过程。
Carcinogenesis. 2021 Feb 11;42(1):118-126. doi: 10.1093/carcin/bgaa058.
4
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果:CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
5
Mechanisms and therapeutic implications of hypermutation in gliomas.胶质母细胞瘤中突变的机制及治疗意义。
Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15.
6
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.人类肿瘤的免疫分析鉴定 CD73 为胶质母细胞瘤的组合靶标。
Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23.
7
Longitudinal molecular trajectories of diffuse glioma in adults.成人弥漫性神经胶质瘤的纵向分子轨迹。
Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.
8
CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling.肿瘤相关巨噬细胞分泌的 CCL8 通过 ERK1/2 信号促进脑胶质母细胞瘤细胞的侵袭和干性。
Lab Invest. 2020 Apr;100(4):619-629. doi: 10.1038/s41374-019-0345-3. Epub 2019 Nov 20.
9
Molecular targeted therapy of glioblastoma.脑胶质瘤的分子靶向治疗。
Cancer Treat Rev. 2019 Nov;80:101896. doi: 10.1016/j.ctrv.2019.101896. Epub 2019 Sep 11.
10
ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.ERK1/2 信号通路调节胶质母细胞瘤中的免疫微环境和巨噬细胞募集。
Biosci Rep. 2019 Sep 13;39(9). doi: 10.1042/BSR20191433. Print 2019 Sep 30.